ACCESS TO VORASIDENIB IN THE UK

VORASIDENIB LATEST

MHRA AND NICE

We are very happy to announce that  Vorasidenib has now been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat Grade 2 Astrocytoma and Oligodenroglioma patients who have IDH 1/2 mutations aged over 12.

Click on the link for full details.

https://www.gov.uk/government/news/vorasidenib-approved-to-treat-patients-12-years-and-older-with-grade-2-astrocytoma-or-oligodendroglioma-with-a-susceptible-idh1-or-idh2-mutation

A NICE committee meeting was held on 18^th September 2025to discuss whether the drug will be available through the NHS.

Astro Brain Tumour Fund Trustees Mary and Dawn attended the meeting remotely and Dawn’s son Shay, who has an LGG, spoke very eloquently at the meeting, as a patient expert,  about his experiences of living with a low grade glioma (LGG) and how his life has improved, both mentally and physically,  since taking the drug through the named patient programme.

The meeting was littered with data and statistics but we hope that the personal experiences quoted will really count when a decision is made.  It’s really difficult for laymen such as us to judge how the meeting went but we are cautiously optimistic for a positive outcome.